Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna and BioNTech Stocks Slipped Today

By Keith Speights - Jun 23, 2021 at 4:32PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Data was presented to a CDC advisory panel suggesting a link between mRNA vaccines and heart inflammation issues in young men.

What happened

Shares of Moderna (MRNA -5.06%) and BioNTech (BNTX -2.91%) were slipping 4.3% and 3%, respectively, as of 3:51 p.m. EDT on Wednesday. The declines came after physicians in a presentation before an advisory panel to the Centers for Disease Control and Prevention (CDC) stated that the companies' COVID-19 vaccines were likely linked to cases of heart inflammation in adolescents and young adults.

So what

The CDC convened the Advisory Committee on Immunization Practices (ACIP) after reviewing initial data that showed higher-than-expected cases of heart inflammation after the second dose of messenger RNA (mRNA) vaccines. The numbers were especially notable in younger men.

Healthcare professional giving a shot to a young man.

Image source: Getty Images.

Moderna and BioNTech, with its big partner Pfizer (PFE -1.40%), have the only mRNA COVID-19 vaccines authorized for use in the U.S. Pfizer stock also fell slightly today, but the declines for the two other biotech stocks were greater mainly because Moderna and BioNTech don't have any products on the market other than their COVID-19 vaccines.

The reported cases of heart inflammation issues, while concerning, are rare. Tom Shimabukuro, deputy director of the CDC's Immunization Safety Office, stated in a presentation to ACIP that current data points to a rate of 12.6 cases per million in individuals between the ages of 12 and 39 within three weeks of receiving the second dose of the mRNA vaccines. 

Now what

The CDC hasn't indicated at this point what steps it might take in response to the potential issues with the Pfizer-BioNTech and Moderna vaccines. However, with the high efficacy and generally positive overall safety profiles for the vaccines, it's unlikely that any actions that would significantly impact the use of the vaccines will be taken. 

Keith Speights owns shares of Pfizer. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$150.00 (-5.06%) $-8.00
Pfizer Inc. Stock Quote
Pfizer Inc.
$48.58 (-1.40%) $0.69
BioNTech SE Stock Quote
BioNTech SE
$147.61 (-2.91%) $-4.43

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.